Clinical Trials Browser

Phase 3 × atezolizumab × Clear all

NCT02997228 2026-03-18

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Phase 3 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03775265 2026-03-18

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT03811002 2026-03-18

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Phase 3 Active not recruiting

544 enrolled 29 charts

Lung Neoplasms

NCT04214262 2026-03-18

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07195695 2026-03-18

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07388524 2026-03-17

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07472517 2026-03-16

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT05862285 2026-03-13

UmbrellaMAX

Phase 3 Recruiting

Neoplasms

NCT05047250 2026-03-11

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05091567 2026-03-10

IMforte

Phase 3 Active not recruiting

660 enrolled 23 charts 1 FDA

Small Cell Lung Carcinoma

NCT07461675 2026-03-10

Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection

Phase 3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT06646276 2026-03-04

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase 3 Recruiting

Small Cell Lung Carcinoma

NCT04660344 2026-02-13

IMvigor011

Phase 3 Active not recruiting

Muscle-invasive Bladder Cancer

NCT04665856 2026-02-13

SKYSCRAPER-02C

Phase 3 Active not recruiting

123 enrolled 26 charts

Small Cell Lung Carcinoma

NCT06712355 2026-02-13

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02912559 2026-02-02

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Phase 3 Active not recruiting

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

NCT04294810 2026-01-30

SKYSCRAPER-01

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT04712643 2026-01-30

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

Neoplasms

NCT04256421 2026-01-28

SKYSCRAPER-02

Phase 3 Completed

490 enrolled 31 charts

Small Cell Lung Carcinoma

NCT03456063 2026-01-22

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Phase 3 Completed

Non-Small-Cell Lung

NCT04543617 2026-01-20

SKYSCRAPER-07

Phase 3 Active not recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04649489 2026-01-15

TALENTOP

Phase 3 Active not recruiting

Venous Thrombosis

NCT03148418 2026-01-13

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Phase 3 Active not recruiting

Neoplasms

NCT06921785 2026-01-09

ARTEMIDE-HCC01

Phase 3 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05112965 2026-01-07

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Phase 3 Active not recruiting

Neoplasms

NCT05904886 2025-12-31

SKYSCRAPER-14

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Phase 3 Completed

190 enrolled 12 charts

Breast Neoplasms

NCT04148911 2025-12-26

EL1SSAR

Phase 3 Completed

184 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT04446117 2025-12-18

CONTACT-02

Phase 3 Active not recruiting

575 enrolled 13 charts

Prostatic Neoplasms

NCT06908993 2025-12-17

COMET

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03755791 2025-12-11

COSMIC-312

Phase 3 Active not recruiting

837 enrolled 14 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05317858 2025-12-10

LIMITLESS

Phase 3 Recruiting

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT06733038 2025-12-08

AtezoTRIBE2

Phase 3 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT03735121 2025-12-05

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 3 Completed

438 enrolled 40 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03977194 2025-11-18

ELDERLY

Phase 3 Active not recruiting

Non Small Cell Lung Cancer Metastatic

NCT03371017 2025-11-12

IMpassion132

Phase 3 Completed

595 enrolled 37 charts

Triple Negative Breast Neoplasms

NCT04540211 2025-10-28

SKYSCRAPER-08

Phase 3 Completed

Gastrointestinal

Esophageal Neoplasms

NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

Phase 3 Active not recruiting

Extensive Stage Small Cell Lung Cancer

NCT03520686 2025-10-16

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04487067 2025-09-22

AMETHISTA

Phase 3 Completed

152 enrolled 16 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04513925 2025-09-08

SKYSCRAPER-03

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT06680258 2025-09-03

A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy

Phase 3 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

NCT04740918 2025-08-08

KATE3

Phase 3 Terminated

96 enrolled 16 charts

Breast Neoplasms

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Phase 3 Completed

514 enrolled 25 charts 2 FDA

Melanoma

NCT05482516 2025-05-22

MRD-GI

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms, Carcinoma, Hepatocellular, Rectal Neoplasms

NCT03603184 2025-05-09

AtTEnd

Phase 3 Completed

Neoplasms, Endometrial Neoplasms

NCT04732286 2025-05-08

A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

Phase 3 Terminated

100 enrolled 18 charts

Gastrointestinal

Carcinoma, Hepatocellular